Anthrax Vaccine Market Report, Global, 2024

The anthrax vaccine market size has grown steadily in recent years. It will grow from $10.74 billion in 2023 to $11.27 billion in 2024 at a compound annual growth rate (CAGR) of 4.9%. The growth observed in the historical period can be attributed to various factors, including concerns related to biological warfare, the demand from military sectors, occurrences of anthrax outbreaks, initiatives for public health preparedness, and the development of biodefense programs.

The anthrax vaccine market size is expected to see strong growth in the next few years. It will grow to $13.8 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The forecast period's growth is expected to be fueled by global security challenges, emerging threats, government procurement initiatives aimed at bolstering defense capabilities, and enhanced pandemic preparedness efforts. Anticipated trends in the forecast period encompass technological advancements in vaccine development, increased accessibility of vaccines in developing countries, a heightened focus on next-generation vaccines, expanded government stockpiling initiatives, and collaborative research efforts aimed at combating infectious diseases.

The anthrax vaccine market is expected to experience significant growth due to the rising prevalence of infectious diseases. Infectious diseases, caused by various pathogens, pose a significant threat to public health, leading to a range of symptoms and sometimes fatal outcomes. Factors contributing to the increased prevalence of infectious diseases include demographic shifts, urbanization, environmental changes, and alterations in human behavior. The anthrax vaccine, primarily designed to protect against anthrax, is being explored for its potential to prevent other infectious diseases, driven by ongoing research into its immunogenic properties and adaptability. As highlighted by the Council on Foreign Relations in February 2023, a considerable percentage of newly discovered or emerging infectious diseases have zoonotic origins, underscoring the need for effective vaccines to mitigate their impact.

Major companies in the anthrax vaccine market are prioritizing the development of innovative products and obtaining FDA approvals to ensure safety, efficacy, and accessibility for individuals at risk of anthrax exposure. FDA approval signifies that a vaccine has undergone rigorous testing in clinical trials and has been deemed safe for public use, providing assurance to individuals regarding its safety profile. For example, Emergent BioSolutions Inc., a leading biopharmaceutical company, received FDA approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) in July 2023. This approval was based on comprehensive Phase 2 and Phase 3 clinical trials evaluating the vaccine's safety and immunogenicity compared to existing anthrax vaccines. Additionally, advancements in adjuvant technology are crucial for addressing reactogenicity concerns and enhancing the overall effectiveness of anthrax vaccines.

In October 2022, the Biomedical Advanced Research and Development Authority (BARDA) partnered with ICON plc and Rho Federal Systems Division Inc. to conduct a clinical trial evaluating the anthrax vaccine AV7909. This trial aims to assess the immunogenicity kinetics of AV7909, which combines the FDA-licensed anthrax vaccine BioThrax with an immune system stimulant. ICON plc, an Ireland-based clinical research organization, and Rho Federal Systems Division Inc., a US-based company specializing in research and development services, are collaborating with BARDA to advance anthrax vaccine research and development.

Major companies operating in the anthrax vaccine market are Merck & Co. Inc., GC Biopharma, Emergent BioSolutions Inc., Indian Immunologicals Limited, Valneva SE, PharmAthene Inc, Porton Biopharma Limited, Pfenex Inc., Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company, Inc., Elusys Therapeutics Inc., SIGA Technologies Inc., Inovio Pharmaceuticals, Botswana Vaccine Institute, JOVAC, Prokarium, Soligenix Inc., Vaxart Inc., DynPort Vaccine Company LLC, VECOL S.A.

North America was the largest region in the anthrax vaccine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anthrax vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anthrax vaccine is a medical product aimed at conferring immunity against anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis. Comprising an inactivated form of the anthrax bacterium or its components, the vaccine stimulates the body's immune response to generate antibodies against anthrax toxins. Typically administered via injections, the vaccine involves initial doses followed by booster shots to sustain immunity over time.

The primary types of anthrax vaccine include the cell-free protective antigen (PA) vaccine and the live attenuated vaccine. The cell-free protective antigen (PA) vaccine is produced in a laboratory environment without live bacteria, involving the synthesis of the anthrax bacteria's protective antigen (PA) protein. These vaccines find applications in both animal and human use and are distributed through various channels such as hospitals, pharmacies, and others.

The anthrax vaccine market research report is one of a series of new reports that provides anthrax vaccine market statistics, including anthrax vaccine industry global market size, regional shares, competitors with a anthrax vaccine market share, detailed anthrax vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the anthrax vaccine industry. This anthrax vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anthrax vaccine market consists of sales of avirulent, nonencapsulated bacillus anthracis microaerophilic cultures, aluminum, benzethonium chloride, and formaldehyde. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.